anti-GD2 + NK cells

Anti-GD2 + NK cells refers to a combination immunotherapy approach that uses an anti-GD2 monoclonal antibody (such as dinutuximab or 3F8) together with adoptively transferred or ex vivo-activated natural killer (NK) cells. GD2 is a disialoganglioside highly expressed on the surface of neuroblastoma and other neuroectodermal tumors but limited in normal tissues, making it an attractive target for immunotherapy. Anti-GD2 antibodies mediate tumor cell killing primarily through antibody-dependent cellular cytotoxicity (ADCC), a process in which immune effector cells such as NK cells recognize and kill antibody-coated tumor targets. The addition of exogenous or activated NK cells enhances this effect by increasing the number and activity of effector immune cells available for ADCC, leading to improved tumor cell lysis compared to either treatment alone. This strategy has been studied preclinically and clinically in high-risk neuroblastoma and is being explored for other GD2-positive malignancies[1][4][6]. The mechanism involves direct targeting of GD2 on tumor surfaces by the monoclonal antibody, with subsequent recruitment and activation of infused or endogenous NK cells to mediate cytotoxicity.

Other names

anti-GD2 antibody plus natural killer cellsanti-GD-2 antibody plus natural killer cellsanti-GD 2 antibody plus natural killer cellsanti-GD2 mAb + NK cell therapydinutuximab + activated NK cells